Journal of Biochemistry and Biotechnology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Editorial - Journal of Biochemistry and Biotechnology (2024) Volume 7, Issue 6

AI and CRISPR: Enhancing Accuracy in Gene Editing

Priya Sharma*

Indian Institute of Bioethics, India

*Corresponding Author:
Priya Sharma
Indian Institute of Bioethics, India
E-mail: priya.sharma@email.com

Received: 04-Dec-2024, Manuscript No. AABB-24-153760; Editor assigned: 05-Dec-2024, Pre QC No. AABB-24-153760 (PQ); Reviewed: 12-Dec-2024, QC No. AABB-24-153760; Revised: 19-Dec-2024, Manuscript No. AABB-24-153760 (R); Published: 26-Dec-2024, DOI:10.35841/aabb-7.6.236

Citation: Sharma P. AI and CRISPR: Enhancing Accuracy in Gene Editing. J Biochem Biotech 2024; 7(6):236.

Visit for more related articles at Journal of Biochemistry and Biotechnology

Introduction

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) has revolutionized genetic engineering by providing a precise and powerful tool for gene editing. The ability to cut and modify specific regions of DNA has enormous potential in fields like medicine, agriculture, and biotechnology. However, like any technology, CRISPR is not without its challenges—particularly when it comes to off-target effects, where unintended parts of the genome are altered. To address these challenges, artificial intelligence (AI) is playing an increasingly important role, enhancing the accuracy, efficiency, and predictability of CRISPR-based gene editing. This article explores how AI and CRISPR are working together to improve gene-editing outcomes and discusses the future potential of this dynamic combination [1].

CRISPR is a gene-editing tool derived from the natural defense mechanisms of bacteria, where it helps protect against viral infections. In the laboratory, scientists have harnessed this system to target and modify genes in a wide variety of organisms. The CRISPR-Cas9 system works by guiding a Cas9 enzyme to a specific DNA sequence, where it creates a cut. This cut is then repaired by the cell's natural mechanisms, allowing for the deletion, insertion, or modification of genes. While the CRISPR system is precise, the possibility of cutting unintended DNA sequences (off-target effects) remains a significant concern, particularly in therapeutic applications where unintended gene edits could have harmful consequences [2].

One of the biggest challenges in CRISPR gene editing is predicting and minimizing off-target effects. AI, particularly machine learning (ML) algorithms, has proven highly effective in addressing this issue. By analyzing vast amounts of genomic data, AI models can predict where off-target cuts are most likely to occur based on the sequence similarity of potential target sites. These predictions help researchers design more accurate CRISPR guides, ensuring that the Cas9 enzyme cuts only at the intended location. Tools like DeepCRISPR and CRISPR-Net utilize AI to significantly improve the specificity of CRISPR by identifying potential off-target sites before gene editing takes place [3].

A prominent example of AI enhancing CRISPR accuracy comes from the development of deep learning models such as DeepCRISPR. This AI tool analyzes large datasets of DNA sequences and their interactions with CRISPR-Cas9 to predict where off-target effects might occur. DeepCRISPR has been shown to reduce off-target activity by up to 50% by providing more precise predictions about where the Cas9 enzyme is likely to cut. This advancement is crucial in therapeutic contexts, where unintended genetic alterations could lead to dangerous side effects, such as cancer or genetic diseases. By using AI to fine-tune CRISPR targeting, researchers are making gene editing safer and more reliable [4].

Guide RNA (gRNA) plays a critical role in CRISPR gene editing, as it directs the Cas9 enzyme to the specific DNA sequence that needs to be edited. Designing an effective gRNA is essential for ensuring accuracy and minimizing off-target effects. AI is transforming this process by predicting the most efficient and specific gRNA sequences. Machine learning models can analyze vast datasets to identify patterns in successful gRNA designs, helping scientists choose or even create gRNAs that are more likely to target the correct DNA sequence with high precision. AI-based tools like CRISPR AI and sgRNA Designer have been developed to optimize guide RNA selection, making CRISPR more effective in both research and clinical settings [5].

Beyond traditional CRISPR-Cas9 gene editing, AI is also enhancing the accuracy of base editors—CRISPR variants that can directly change one DNA base into another without cutting the DNA. Base editors offer a less invasive alternative to standard CRISPR, with fewer risks of double-strand breaks. However, like CRISPR-Cas9, base editors can also have off-target effects. AI models have been developed to improve the targeting accuracy of base editors by predicting which bases are most likely to be successfully edited and which are at risk for off-target effects. These AI-driven insights have made base editing a more reliable tool for gene correction, especially in treating genetic diseases [6].

Another area where AI is making significant contributions is in predicting the outcomes of CRISPR edits. AI models can simulate the cellular repair processes that follow CRISPR-induced cuts, helping researchers anticipate whether the gene will be correctly modified, deleted, or repaired in unintended ways. This predictive capability is essential in therapeutic applications, where researchers need to ensure that the desired gene alteration occurs without introducing harmful side effects. AI tools like InDelphi and FORECasT use machine learning to model DNA repair outcomes, providing researchers with crucial information about the likely results of CRISPR edits before they are conducted [7].

In addition to enhancing gene-editing accuracy, AI and CRISPR are also revolutionizing drug discovery. CRISPR allows researchers to create precise genetic models of diseases, while AI helps identify potential drug targets within these models. By combining CRISPR’s ability to manipulate specific genes with AI’s pattern recognition capabilities, scientists can more quickly identify which genetic mutations cause disease and which molecules might be used to treat them. This powerful combination is accelerating the development of new therapies for complex conditions such as cancer, neurodegenerative diseases, and genetic disorders [8].

The integration of AI and CRISPR raises several ethical concerns, particularly regarding the potential for human genetic modification. While AI enhances the safety and accuracy of gene editing, concerns about germline editing (which alters the DNA of future generations) and the use of CRISPR for non-therapeutic purposes, such as human enhancement, remain pressing. Additionally, AI’s role in automating and optimizing genetic modifications highlights the need for robust regulatory frameworks to prevent misuse. As AI and CRISPR continue to evolve, ethical oversight will be crucial in ensuring that these powerful technologies are used responsibly [9].

As AI and CRISPR technologies continue to advance, their synergy will likely lead to even more precise and powerful gene-editing tools. Future developments may include AI-driven platforms capable of autonomously designing, testing, and optimizing CRISPR-based therapies, significantly accelerating the pace of genetic research and clinical applications. The potential for CRISPR to treat genetic diseases, enhance agricultural crops, and create new biotechnological innovations will be expanded by AI’s ability to analyze and predict outcomes with unprecedented accuracy. The future of gene editing, powered by AI, holds tremendous promise for advancing both human health and scientific discovery [10].

Conclusion

AI and CRISPR represent a powerful combination at the forefront of genetic engineering. By enhancing the accuracy, efficiency, and predictability of CRISPR gene editing, AI is transforming the possibilities for treating genetic diseases, improving agricultural practices, and advancing drug discovery. However, the rapid pace of development also raises important ethical and regulatory questions that must be addressed to ensure these technologies are used safely and responsibly. As AI and CRISPR continue to evolve, their potential to reshape science, medicine, and society is immense, offering a glimpse into a future where genetic editing is both precise and commonplace.

References

  1. Barrangou R, Doudna JA. Applications of CRISPR technologies in research and beyond. Nat Biotechnol. 2016;34(9):933-41.

    2. Indexed at, Google Scholar, Cross Ref

  2. Wang L, Zhang J. Prediction of sgRNA on-target activity in bacteria by deep learning. BMC Bioinformatics. 2019;20:1-4.

    3. Indexed at, Google Scholar, Cross Ref

  3. Liu G, Zhang Y, Zhang T. Computational approaches for effective CRISPR guide RNA design and evaluation. Comput Struct Biotechnol J. 2020;18:35-44.

    4. Indexed at, Google Scholar, Cross Ref

  4. Kleinstiver BP, Pattanayak V, Prew MS. High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016;529(7587):490-5.

    5. Indexed at, Google Scholar, Cross Ref

  5. Dai M, Li X, Zhang Q. Health research in the era of artificial intelligence: Advances in gene-editing study. Medicine. 2024:100027.

    6. Indexed at, Google Scholar, Cross Ref

  6. de Boer J. Attention-based deep learning for DNA repair outcome prediction.

    7. Google Scholar

  7. Dunka V. Integrating AI with CRISPR Technology: Enhancing Gene Editing Precision and Efficiency. J Deep Learn Genomic Data Anal. 2024;4(2):150-90.

    8. Google Scholar

  8. Das S, Bano S, Kapse P. CRISPR based therapeutics: a new paradigm in cancer precision medicine. Mol Cancer. 2022;21(1):85.

    9. Google Scholar

  9. Ghosh S, Bhaskar R, Sinha JK. Balancing potential benefits and ethical considerations of gene editing. Lancet. 2023;401(10394):2109-10.

    10. Indexed at, Google Scholar, Cross Ref

  10. Khalil A. Precision oncology in the era of CRISPR-Cas9 technology. Front Genet. 2024;15:1506627.

    11. Indexed at, Google Scholar, Cross Ref

Get the App